Eden, a Mexican cloud radiology platform, announced on 10 October 2025 a USD 22 million Series A led by Sierra Ventures. It matters because it is growth capital for clinical infrastructure with proven usage in 18 countries, and because the round puts a Silicon Valley fund and a top-tier Mexican business leader at the same table.
The transaction
Series A of USD 22 million. Lead investor: Sierra Ventures. Liquid 2 Ventures and Daniel Servitje, chief executive of Grupo Bimbo, participated. Valuation and instrument were not disclosed. The company had raised USD 10 million in 2024; prior investors include Khosla Ventures, Kaszek and Hummingbird. On cumulative capital the sources disagree: Forbes Colombia reports more than USD 36 million; Contxto, around USD 57 million, counting an additional USD 25 million round. We could not reconcile the two figures with public information.
Eden is led by Julián Ríos Cantú, co-founder and chief executive. Its product is a cloud-native radiology operating system (RIS/PACS) with artificial intelligence tools for diagnostic assistance and, according to Contxto, a module for automated clinical report generation. It serves more than 2,200 medical institutions in 18 countries and processes more than 13 million studies a year. Proceeds will fund expansion in Colombia and other markets in the region, entry into the United States, diagnostic AI development and technology infrastructure.
Value drivers
Infrastructure, not an application. A RIS/PACS is the system of record of an imaging service: replacing it carries a high operating cost. In our reading, the price pays for an installed-system position in more than 2,200 institutions, with structural retention a clinical app does not have.
Data volume as an option on AI. Thirteen million studies a year are the input to train and validate diagnostic models inside the radiologist’s workflow. The company presents AI as a use of proceeds, not as a current revenue source; the distinction matters when projecting.
Regional coverage. Eighteen countries from Mexico give Eden a basis of comparison with global imaging vendors that sell per hospital and in dollars in Latin America. It is our interpretation that a price discount to those vendors explains part of the adoption; the sources do not quantify it.
Composition of the table. A leading Silicon Valley fund, an early-stage fund and a Mexican business leader with access to the country’s private sector. For a fund reader, the signal is that the company is seeking doors into Mexican hospitals and insurers as much as capital.
What the market is signalling
For Mexico, the signal is that clinical software infrastructure continues to attract growth capital when there is measurable usage per study and per institution. Local comparables with hospital or laboratory management systems should expect funds to measure studies processed and retention per institution, not only contracts signed.
For strategic buyers, a vendor with 2,200 institutions is both partner and threat: a hospital group or an imaging equipment manufacturer may see Eden as a channel or as a competitor in the data layer. For lenders, recurring revenue per institution with low churn is the basis for a venture debt line, although no source reports debt at the company.
G2’s reading for a mandate
When public sources disagree on cumulative capital, the next round’s memorandum must present a reconciled cap table from day one; an investment committee spots the inconsistency before the founder does. For a Series B, preparation means separating infrastructure revenue from AI revenue, documenting retention per institution and supporting the US entry with a regulatory and sales plan independent from the regional one.
Sources
- LatamList, 10 October 2025: Eden raises $22M Series A
- Forbes Colombia, 10 October 2025: Healthtech Eden levanta US$22 millones para llevar su sistema operativo de radiología a más países
- Contxto, 10 October 2025: Eden closes $22 million Series A round led by global funds